Vir Biotechnology sells 17.6 million shares at $8.50 each in public offering
Vir Biotechnology entered into an underwriting agreement on February 25, 2026, to sell 17,647,059 shares of common stock at $8.50 per share. The company expects net proceeds of about $141.1 million, or about $162.3 million if underwriters fully exercise their option for additional shares, but the sale adds new shares outstanding, which dilutes existing shareholders.
Key points
- Offering of 17,647,059 common shares at $8.50 per share, with underwriters led by Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc.
- Expected net proceeds of approximately $141.1 million, or approximately $162.3 million if the underwriters' option is fully exercised.
- Underwriters hold a 30-day option to buy up to 2,647,058 additional shares at the public offering price.
- Offering is expected to close on February 27, 2026, subject to customary closing conditions.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.